---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-010974"
form_type: "8-K"
ticker: "AVBP"
cik: "0001868279"
company_name: "ArriVent BioPharma, Inc."
filed_at: "2025-08-11T23:59:59+00:00"
generated_at: "2026-05-17T15:45:46.876781+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# ArriVent Q2 2025 net loss $95.8M; firmonertinib PACC data positive; ADC ARR-217 dosed

## Summary
- Cash and investments $254.5M at June 30, plus $81.1M raised in July 2025 public offering; runway extended to mid-2027.
- Net loss $95.8M for H1 2025 vs. $39.3M in H1 2024; R&D expense $89.0M including $40M one-time upfront to Lepu BioPharma.
- Positive interim Phase 1b data for firmonertinib in EGFR PACC mutant NSCLC; final data at WCLC September 2025.
- First patient dosed in Phase 1 for ARR-217 (CDH17-targeted ADC) in gastrointestinal tumors by partner Lepu.
- Top-line firmonertinib data from FURVENT Phase 3 for EGFR Exon20 insertion expected early 2026; PACC Phase 3 ALPACCA enrollment in 2H 2025.

## SEC filing metadata
- accession: 0001558370-25-010974
- form_type: 8-K
- ticker: AVBP
- cik: 0001868279
- company_name: ArriVent BioPharma, Inc.
- filed_at: 2025-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1868279/000155837025010974/0001558370-25-010974-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1868279/000155837025010974/avbp-20250811x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-010974
- JSON: https://secwatch.observer/filing/0001558370-25-010974.json
- Plain text: https://secwatch.observer/filing/0001558370-25-010974.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.